In older adults with type 2 diabetes (T2D), the initiation of GLP-1 receptor agonists vs drugs such as DPP-4 and SGLT2 inhibitors was associated with an 11% increased risk for fragility fractures.
Overall, 4086 new incidences of fragility fractures were recorded over 147,250 person-years, with femur fractures being the most common, accounting for 26.7% of the fractures that occurred first.
The increased risk for fractures was significant among individuals aged 65-75 years (HR, 1.26; P < .001) but not among those aged 75 years or older.